Incidence and duration of cumulative bisphosphonate use among community-dwelling persons with or without Alzheimer’s disease
Manuscript Number:
15-1181R1
Author(s):
Sirpa Hartikainen, Heidi Taipale, Antti Tanskanen, Jari Tiihonen, Miia Tiihonen
Disclosures
Sirpa Hartikainen
Nothing to Disclose
Heidi Taipale
Nothing to Disclose
Antti Tanskanen
Nothing to Disclose
Jari Tiihonen
Consulting Fees:
Serving as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Janssen-Cilag, Lundbeck, and Organon. Member of advisory boards in AstraZeneca, Eli Lilly, Janssen-Cilag, and Otsuka. Received fees for giving expert opinions to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Otsuka, and Pfizer.
Lecture Fees:
Lecture fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Novartis, Otsuka, and Pfizer.